Intensity Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell INTS and other ETFs, options, and stocks.About INTS
Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine.
CEOLewis H. Bender
CEOLewis H. Bender
Employees16
Employees16
HeadquartersShelton, Connecticut
HeadquartersShelton, Connecticut
Founded2012
Founded2012
Employees16
Employees16
INTS Key Statistics
Market cap27.58M
Market cap27.58M
Price-Earnings ratio-0.73
Price-Earnings ratio-0.73
Dividend yield—
Dividend yield—
Average volume2.81M
Average volume2.81M
High today$0.49
High today$0.49
Low today$0.3451
Low today$0.3451
Open price$0.4426
Open price$0.4426
Volume13.77M
Volume13.77M
52 Week high$3.17
52 Week high$3.17
52 Week low$0.1853
52 Week low$0.1853
Stock Snapshot
The current Intensity Therapeutics(INTS) stock price is $0.46, with a market capitalization of 27.58M. The stock trades at a price-to-earnings (P/E) ratio of -0.73.
On 2025-12-05, Intensity Therapeutics(INTS) stock moved within a range of $0.35 to $0.49. With shares now at $0.46, the stock is trading +33.5% above its intraday low and -6.0% below the session's peak.
Trading activity shows a volume of 13.77M, compared to an average daily volume of 2.81M.
The stock's 52-week range extends from a low of $0.19 to a high of $3.17.
The stock's 52-week range extends from a low of $0.19 to a high of $3.17.
People also own
Based on the portfolios of people who own INTS. This list is generated using Robinhood data, and it’s not a recommendation.